Jarade C, Zolotarova T, Moiz A, Eisenberg MJ
despite being taken as a daily pill rather than injection, it contains the same active ingredient and allegedly carries similar risks Mounjaro (tirzepatide): Manufactured by Eli Lilly and approved in May 2022, this medication works as a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist, offering enhanced blood sugar control and weight loss effects but also allegedly causing severe gastrointestinal injuries similar to semaglutide products Trulicity (dulaglutide): Eli Lillys once-weekly GLP-1 injection approved in 2014 for type 2 diabetes
Published protocols Animal-model studies commonly report 10500 g/kg/day in rat models, administered intraperitoneally or subcutaneously over the experimental window
Addiction/mental health A study of more than 2 million people with diabetes taking the popular weight-loss drugs found the medications were associated with reduced risks of seizures and addiction to substances such as alcohol, cannabis, stimulants and opioids
2018 Dec 6;19(12):3903
showed that a choline-deficient diet in humans modulates the gut bacteria with altered levels of Gammaproteobacteria and Erysipelotrichi and this is directly associated with fatty liver development [61]
